Novel Therapies for Eosinophilic Disorders

Bruce S. Bochner

Research output: Contribution to journalArticle

Abstract

Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.

Original languageEnglish (US)
Pages (from-to)577-598
Number of pages22
JournalImmunology and Allergy Clinics of North America
Volume35
Issue number3
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Eosinophils
Off-Label Use
Controlled Clinical Trials
Biological Products
Glucocorticoids
Therapeutics
Inflammation

Keywords

  • Antibodies
  • Biomarkers
  • Eosinophil
  • Pharmacology
  • Targets
  • Therapies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Novel Therapies for Eosinophilic Disorders. / Bochner, Bruce S.

In: Immunology and Allergy Clinics of North America, Vol. 35, No. 3, 01.08.2015, p. 577-598.

Research output: Contribution to journalArticle

Bochner, Bruce S. / Novel Therapies for Eosinophilic Disorders. In: Immunology and Allergy Clinics of North America. 2015 ; Vol. 35, No. 3. pp. 577-598.
@article{02f153f24e3a4eccbe384688a624e562,
title = "Novel Therapies for Eosinophilic Disorders",
abstract = "Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.",
keywords = "Antibodies, Biomarkers, Eosinophil, Pharmacology, Targets, Therapies",
author = "Bochner, {Bruce S.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.iac.2015.05.007",
language = "English (US)",
volume = "35",
pages = "577--598",
journal = "Immunology and Allergy Clinics of North America",
issn = "0889-8561",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Novel Therapies for Eosinophilic Disorders

AU - Bochner, Bruce S.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.

AB - Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.

KW - Antibodies

KW - Biomarkers

KW - Eosinophil

KW - Pharmacology

KW - Targets

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=84937692015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937692015&partnerID=8YFLogxK

U2 - 10.1016/j.iac.2015.05.007

DO - 10.1016/j.iac.2015.05.007

M3 - Article

VL - 35

SP - 577

EP - 598

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

SN - 0889-8561

IS - 3

ER -